Functional recovery in parkinsonian monkeys treated with GDNF
暂无分享,去创建一个
B. Hoffer | Zhiming Zhang | D. Russell | F. Collins | W. Cass | D. Gash | A. Ovadia | A. Yi | L. Simmerman | David Martin | P. Lapchak | Greg A. Gerhard | Aliza Ovadia | David W. Martin | Ai Yi
[1] John L. Hudson,et al. Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo , 1995, Brain Research Bulletin.
[2] B J Hoffer,et al. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys , 1995, The Journal of comparative neurology.
[3] Don M. Gash,et al. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys , 1995, Neurobiology of Aging.
[4] A. Granholm,et al. Glial cell line‐derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons , 1995, The Journal of comparative neurology.
[5] K. Double,et al. Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[6] D. Gash,et al. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo , 1995, Brain Research.
[7] R. Vandlen,et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain , 1995, Nature.
[8] L. Olson,et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.
[9] John L. Hudson,et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo , 1994, Neuroscience Letters.
[10] R. Kurlan,et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease , 1994, Annals of neurology.
[11] G. M. Halliday,et al. Practical considerations for the use of the optical disector in estimating neuronal number , 1994, Journal of Neuroscience Methods.
[12] M. Sofroniew,et al. Trophism, Transplantation, and Animal Models of Parkinson's Disease , 1993, Experimental Neurology.
[13] Mark J. West,et al. New stereological methods for counting neurons , 1993, Neurobiology of Aging.
[14] J. Lile,et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.
[15] Z. Zhang,et al. Developing a stable bilateral model of parkinsonism in rhesus monkeys , 1993, Neuroscience.
[16] Richard E. Coggeshall,et al. A consideration of neural counting methods , 1992, Trends in Neurosciences.
[17] M. Delong,et al. Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.
[18] H. Robertson,et al. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[19] G. Robertson,et al. Evidence that the substantia nigra is a site of action for l-DOPA , 1988, Neuroscience Letters.
[20] K. Jellinger,et al. Overview of morphological changes in Parkinson's disease. , 1987, Advances in neurology.
[21] S J Kish,et al. Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.
[22] D. Jacobowitz,et al. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.